Literature DB >> 10718208

Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer.

M M Aubele1, M C Cummings, A E Mattis, H F Zitzelsberger, A K Walch, M Kremer, H Höfler, M Werner.   

Abstract

Carcinoma of the breast is thought to evolve through a sequential progression from normal to proliferative epithelium and eventually into carcinoma. Here lumpectomy specimens from five patients were studied, selected for the presence of ductal hyperplasia without atypia, atypical ductal hyperplasia, ductal carcinoma in situ, and invasive ductal carcinoma. Laser microdissection of tissue allowed precise sampling and direct correlation of phenotypic and genotypic changes. Analyses of the samples revealed an increasing mean number of chromosomal changes occurring with increasing histologic severity, and for the first time chromosomal abnormalities were demonstrated in ductal hyperplasia without atypia. Chromosomal changes found in each of the four histologic entities included gains on 10q, 12q, 16p, and 20q and loss on 13q. In ductal hyperplasia without atypia, gain on 20q as well as loss on 13q was detected with high frequency (four of five samples). Alterations identified in more than 50% of atypical ductal hyperplasia samples included gains on 3p, 8q, 15q, and 22q and loss on 16q. In ductal carcinoma in situ, gain of DNA on 1q and 17q and loss on 4q were additionally found, and in invasive ductal carcinoma, further gains on 6p, 10q, 11q13, and 17p were identified. The chromosomal alterations occurring in the different histopathologic lesions strongly suggest that these regions harbor tumor suppressor genes or oncogenes significant for the development of ductal carcinoma of the breast.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718208     DOI: 10.1097/00019606-200003000-00003

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  13 in total

1.  DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions.

Authors:  Colleen Fordyce; Tim Fessenden; Curtis Pickering; Jason Jung; Veena Singla; Hal Berman; Thea Tlsty
Journal:  Cancer Prev Res (Phila)       Date:  2009-12-22

2.  Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study.

Authors:  Lynn C Hartmann; Derek C Radisky; Marlene H Frost; Richard J Santen; Robert A Vierkant; Lorelle L Benetti; Yaman Tarabishy; Karthik Ghosh; Daniel W Visscher; Amy C Degnim
Journal:  Cancer Prev Res (Phila)       Date:  2014-01-30

Review 3.  Genome evolution in ductal carcinoma in situ: invasion of the clones.

Authors:  Anna K Casasent; Mary Edgerton; Nicholas E Navin
Journal:  J Pathol       Date:  2016-11-27       Impact factor: 7.996

Review 4.  The Activin Social Network: Activin, Inhibin, and Follistatin in Breast Development and Cancer.

Authors:  Darcie D Seachrist; Ruth A Keri
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

5.  Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas.

Authors:  Pamela S Larson; Antonio de las Morenas; Sheila R Bennett; L Adrienne Cupples; Carol L Rosenberg
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

6.  Genomic instability demonstrates similarity between DCIS and invasive carcinomas.

Authors:  Christopher M Heaphy; Marco Bisoffi; Nancy E Joste; Kathy B Baumgartner; Richard N Baumgartner; Jeffrey K Griffith
Journal:  Breast Cancer Res Treat       Date:  2008-09-11       Impact factor: 4.872

7.  Specific genes expressed in association with progesterone receptors in meningioma.

Authors:  Elizabeth B Claus; Peter J Park; Rona Carroll; Jennifer Chan; Peter M Black
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

8.  Cyclin E and FGF8 are downstream cell growth regulators in distinct tumor suppressor effects of ANXA7 in hormone-resistant cancer cells of breast versus prostate origin.

Authors:  A Bera; X-M Leighton; H Pollard; M Srivastava
Journal:  Trends Cancer Res       Date:  2018

9.  Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells.

Authors:  Matteo Fassan; Domenico D'Arca; Juraj Letko; Andrea Vecchione; Marina P Gardiman; Peter McCue; Bernadette Wildemore; Massimo Rugge; Dolores Shupp-Byrne; Leonard G Gomella; Andrea Morrione; Renato V Iozzo; Raffaele Baffa
Journal:  PLoS One       Date:  2011-05-06       Impact factor: 3.240

10.  MITOSTATIN, a putative tumor suppressor on chromosome 12q24.1, is downregulated in human bladder and breast cancer.

Authors:  A Vecchione; M Fassan; V Anesti; A Morrione; S Goldoni; G Baldassarre; D Byrne; D D'Arca; J P Palazzo; J Lloyd; L Scorrano; L G Gomella; R V Iozzo; R Baffa
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.